Strategic Partnerships Sedia Biosciences has formal distribution and collaboration activity with Thermo Fisher Scientific as of March 2026, presenting a pathway to co-sell or bundle services with a leading genomics supplier.

Regulatory Milestones Recent WHO Pre-Qualification for the Asanté HIV-1/2 Oral Fluid Test and ISO 13485 certification indicate strong quality and global market eligibility, signaling readiness for international sales expansion and preferred supplier status.

Genomics & Surveillance A history of genomics and sequencing services (including Sedia COVID-19 WGS) and a track record of HIV-focused testing positions the company to target labs and public health programs needing sequencing and variant surveillance capabilities.

Small Team, Global Impact With a lean team yet strategic partnerships and certifications, there is potential to scale through channel partnerships, CRO collaborations, and distributor networks to accelerate market reach.

Funding Signals Revenue in the low millions suggests growth opportunities through expanded product lines, OEM opportunities, and renewed bids in global health programs seeking validated HIV diagnostics and genomics solutions.